Actavis business

1

• Actavis business
• in Russia

Jonas Tryggvason Executive Vice President Actavis
CEEA SM
Reykjavik, May 09, 2007
2
Forward-looking statements
Any statement contained in this presentation
that refers to Actavis estimated or
anticipated future results or future
activities are forward-looking statements which
reflect the Companys current analysis of
existing trends, informationand plans. These
forward-looking statements are subject toa
number of risks and uncertainties that could
cause actual results to differ materially
depending on factors such as the availability of
resources, the timing and effect of regulatory
actions, the success of new products,
the strength of competition, the success of
research and development issues, unexpected
contract breaches or terminations, exposure to
product liability and other lawsuits, the
effect of currency fluctuations and other
factors. Actavis does not undertakethe
obligation to update or alter these
forward-looking statements beyond  its duties
as an issuer of listed securitieson the Iceland
Stock Exchange.
3
Our vision
To be a leading companyin the development,
manufacture and salesof first-class generic
pharmaceuticalsin the international market
4
We realise our vision by......

• .. persistently delivering new products from our
  strong pipeline
• .. penetrating new markets and leveraging our
  strong position in current markets
• .. having an aggressive approach to battling cost
• .. using global strength and local know-how

5
Actavis GroupOrganizational structure
CEO Robert Wessman
Deputy to the CEO Sigurdur Oli Olafsson
US Commercial Admin Doug Boothe
CEEA Sales Marketing Jonas Tryggvason
Third-party Sales Gudbjorg Edda Eggertsdottir
WEMEA Sales Marketing Svend Andersen
Quality Compliance Gudrun Eyjolfsdottir
Finance IT Mark Keatley
Corporate Funding Matthias Johannessen
Merger Acquisition Doug Drysdale
Research Development Stefan J Sveinsson
Legal Henriette Nielsen
Operation US Steinthor Palsson

• Manufacturing
• CAPEX
• Engineering
• EHS

In - licensing Einar G. Hreinsson
Operation EUR ROW Aidan Kavanagh
HR Org. Development Gunnar A. Beinteinsson

• Global scouring
• PTC
• Supply chain optimisation
• Product transfers
• SOP

Supply Chain Management Fearghal Murphy
Corp. Communications Halldor Kristmannsson
Product Launches Gael Bernard
6
Track record of outstanding value creation
7
A remarkable growth story
Actavis in 1999
Actavis today

• 146 employees
• Presence in 1 country
• EUR57 million in sales

• About 11,000 employees
• Present in 32 countries
• EUR1.4 billion in sales
• 650 products on the market
• 355 projects in pipeline
• 24 billion tablets/capsules capacity and strong
  accessto low-cost manufacturing

8
Major acquisitions milestones
2005 Lotus Labs India
2006 Sindan Romania
1999 Balkanpharma Bulgaria
2002 Zdravlje Serbia
2002 UNPDenmark
2001 Pharmamed Malta
2006 ZiO Zdorovje Russia
2005 AmideUSA
2004 FakoTurkey
2005 Higia Bulgaria
2002 Pharmaco Delta merger
2006 Abrika USA
2004 Biovena Poland
2006/7 Grandix Sanmar India
2002Omega FarmaIceland
2005 Alpharma
9
Recent strategic acquisitions
Lotus Labs India February 2005
Amide USA May 2005
Biovena Poland January 2005
Pharma Avalanche Czech Slovak Feb 2005
Higia Bulgaria September 2005
Kéri Pharma Hungary September 2005
Alpharma September 2005
Sindan Romania March 2006
ZiO-Zdorovje Russia November 2006
Abrika USA November 2006
Grandix India December 2006
10
Our track record
Over 20 acquisitions in 7 years12 acquisitions
last 18 months11.000 employees integrated since
1999
Profitability enhancedSales increased pipeline
enhancedCost reduced Organisations right
sizedCustomer and employee retention
highIntegration plans on trackFlexibility and
motivation to adjust surprises
11
Creating shareholder value
Revenue
Market value
March 2007 EUR3 bln
EURmm
EURmm
Revenue guidance for 2006 is EUR1.39 billion,
with EBITDA margin of 20.5
12
Well placed in key markets
Finished products EUR1,379 million in 12M

• Breakdown of sales includes sales and
  distribution of finished goods
• Revenues in Bulgaria include the distribution
  business of Higia, acquired in 2005

13
Actavis in the Russian market

• 1999 opening of Actavis Representative office
  in Russia
• Actavis market share 0.97 of total
  market 1.12 of generic market
• Sales revenue in 2006 EUR 50.9 million
• Number of employees 167
• Sales to pharmacies 90

14
Actavis Representative Office in Russia
15
Actavis all over Russia

• Actavis sales representatives work in all federal
  districts of Russia
• Moscow / Moscovskaya oblast
• North-west (St.Petersburg, Kaliningrad,
  Leningraskaya oblast)
• Volga-river District (Nizhniy Novgorod, Ufa,
  Kazan, Saratov, Toliatty, Penza, Orenburg,
  Ulianovsk, Samara)
• Central Russia (Tambov, Lipetsk, Orel, Rjazan,
  Yaroslavl, Voronezh,Kursk, Tver, Tula, Smolensk)
• South (Krasnodar, Rostov-na-Donu, Astrakhan,
  Stavropol, Volgograd)
• Ural (Perm, Cheljabinsk, Tjumen, Ekaterinburg)
• Siberia and Far East (Krasnoyarsk, Irkutsk,
  Novosibirsk, Barnaul,Kemerovo, Tomsk, Khabarovsk)

16
Sales trend 2000-2007
17

• Trend of personnel growth
• 2000-2007

18
TOP players on the retail market
Market share,
nr.19
19
New Actavis warehousein Russia

• Territory - 1046 sq.meters
• Volume - 2322 pallets

20
Actavis expands presence in Russia

• Purchase of majority stake in Russian
  manufacturing facility strengthens position in
  fast growing market
• In November 2006 Actavis acquired a 51
  controlling interestin ZiO-Zdorovje, one of the
  leading Russian pharmaceutical manufacturer.
• Strategic Rationale
• Russia is one of the fastest growing markets in
  the genericindustry with growth forecast at an
  annual rate of 15-17 during next 5 years. Russia
  is already Actavis' seventh largest market,
  accounting for approximately 4 of the Groups
  annual sales.
• The transaction will enable Actavis to transfer
  production of certain products to Russia and
  provide the Group with a local manufacturing
  presence that will help to facilitate
  participationin state hospital tenders.

21
About ZiO-Zdorovje

• Established in 2001
• Located in Podolsk (about 20 km from Moscow)
• 140 employees
• Current technical capacity is appr. 2 billion
  tablets and capsulesand 20 million sachets a
  year
• The factory is GMP approved
• One of the first Russian manufacturers to get ISO
  90012000 certificates
• Produces 12 generic medicines and sells mainly
• to state medical institutions and through
• the Russian federal reimbursement program
• Forecasting revenues EUR 31 million in 2007

22
Successfulcooperation
23
Thank you!
Jonas Tryggvason, EVP CEEA SM Tel 354 535
2300 Irina Moustiatsa, Country Manager Actavis
Russia Tel [phone] Actavis
Representative Office in Russia Trubnaya street
17/4, building 2 Moscow, 127051 Russia web
www.actavis.ru e-mail info_at_actavis.ru